Kisako Fujiwara, Takayuki Kondo, Kentaro Fujimoto, Sae Yumita, Keita Ogawa, Takamasa Ishino, Miyuki Nakagawa, Terunao Iwanaga, Satoshi Tsuchiya, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Sadahisa Ogasawara, Shingo Nakamoto, Tetsuhiro Chiba, Jun Koizumi, Jun Kato, Naoya Kato
BACKGROUND: During systemic therapy, the management of portal hypertension (PH)-related complications is vital. This study aimed to clarify factors associated with the incidence and exacerbation of PH-related complications, including the usefulness of contrast-enhanced computed tomography (CECT) in the management of PH-related complications during systemic therapy. METHODS: A total of 669 patients who received systemic therapy as first-line treatment (443 patients for sorafenib, 131 for lenvatinib, and 90 for atezolizumab/bevacizumab [ATZ/BEV]) were enrolled in this retrospective study...
April 7, 2024: Journal of Gastroenterology